184 related articles for article (PubMed ID: 28042137)
1. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.
Setiawan D; Luttjeboer J; Pouwels KB; Wilschut JC; Postma MJ
Jpn J Clin Oncol; 2017 Mar; 47(3):265-276. PubMed ID: 28042137
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis.
Guo J; Guo S; Dong S
Front Public Health; 2023; 11():1128717. PubMed ID: 36875363
[TBL] [Abstract][Full Text] [Related]
4. HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.
Mac Eochagain C; Power R; Parker I; Brennan D
J Gynecol Oncol; 2022 May; 33(3):e24. PubMed ID: 35128855
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis.
Li Y; Zhu P; Wu M; Zhang Y; Li L
Vaccine; 2020 Jan; 38(2):119-134. PubMed ID: 31831220
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.
Lichter K; Krause D; Xu J; Tsai SHL; Hage C; Weston E; Eke A; Levinson K
Obstet Gynecol; 2020 May; 135(5):1070-1083. PubMed ID: 32282601
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
Luna J; Plata M; Gonzalez M; Correa A; Maldonado I; Nossa C; Radley D; Vuocolo S; Haupt RM; Saah A
PLoS One; 2013; 8(12):e83431. PubMed ID: 24391768
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
Arbyn M; Xu L
Expert Rev Vaccines; 2018 Dec; 17(12):1085-1091. PubMed ID: 30495978
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
Hildesheim A; Wacholder S; Catteau G; Struyf F; Dubin G; Herrero R;
Vaccine; 2014 Sep; 32(39):5087-97. PubMed ID: 25018097
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
15. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC; Zanini RR
Int J Gynecol Cancer; 2009 Oct; 19(7):1166-76. PubMed ID: 19823051
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol.
Gonçalves CA; Lopes-Júnior LC; Nampo FK; Zilly A; Mayer PCM; Pereira-da-Silva G
BMJ Open; 2019 Jul; 9(7):e026975. PubMed ID: 31320349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
